Sprint Bioscience AB (publ) (STO:SPRINT)

Market Cap	362.97M +373.8%
Revenue (ttm)	139.36M +133.9%
Net Income	75.65M
EPS	0.71
Shares Out	105.52M
PE Ratio	4.87
Forward PE	14.78
Dividend	n/a
Ex-Dividend Date	n/a

Volume	372,199
Open	3.580
Previous Close	3.600
Day's Range	3.440 - 3.630
52-Week Range	0.578 - 4.590
Beta	-0.63
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 3, 2026

About Sprint Bioscience AB

Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of drug candidates to treat cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; DCPS which is in preclinical trial for the treatment of acute myeloid leukemia; VRK1, which is in preclinical development to treat solid tumors; VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; and NNMT for the treatment of solid tumors/chronic kidney diseases...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2009
• Employees: 32
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: SPRINT

Financial Performance

Data Sources: S&P Global Market Intelligence and QUODD

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by QUODD.

Last checked:

Nov 2, 2026

Data Sources Report a data error